Pelthos Therapeutics
Florida, United States · Biotechnology, Health Care, Pharmaceutical · 83 employees
Pelthos Therapeutics Inc. was formerly known as Chromocell Therapeutics Corp. Pelthos Therapeutics specializes in developing treatments for molluscum contagiosum infections. The company is known for its FDA-approved drug ZELSUVMI, which is the first prescription treatment for home use. Pelthos is committed to advancing patient care through innovative therapeutic solutions. It operates as a subsidi
Funding history
- Venture - Series Unknown — $18.0M — Nov 2025
- Venture - Series Unknown — $50.1M — Jul 2025
- Venture - Series Unknown — $750K — Aug 2024
Recent signals
- Apr 10, 2026: Pelthos Therapeutics Appoints John M. Gay as Chief Financial Officer
- Nov 19, 2025: Raised $18.0M in Venture - Series Unknown
- Jul 10, 2025: Raised $50.1M in Venture - Series Unknown
- Aug 06, 2024: Raised $750K in Venture - Series Unknown
See plans & pricing → Track Pelthos Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.